Integra LifeSciences Holdings Corporation IART

SEC filings · Reporting currency USD · Quarterly reporting · Figures as of 2026-Q2 · updated 2026-09-04 · ISIN US4579852082

Net income turned positive Cash flow inflection Guidance cut strategy: Strategic pivot

The new quarter, in context. · We follow every stock through its original filings: the latest figures against their history, guidance against actuals; neutral, continuously updated, every figure clickable with its source.

AI-generated report · not investment advice · figures extracted automatically; please verify against the linked original more

AI-generatedCreated with AI assistance from the company's linked original filings (transparency per Art. 50 EU AI Act). More about the tool: Claude Code.

Not investment adviceNeutral financial information, no recommendation, no investment research within the meaning of MiFID II.

Verify yourselfFigures are extracted automatically, errors are possible. Every figure is clickable with its source; the issuer's original documents are always authoritative.

EditorialThe texts (business model, current status, development and others) are written AI-editorially from the original reports alone, cross-checked automatically and backed with sources; the company's own account, no assessment of our own. Methodology

AI research · This page works as a source-backed data basis for further research with AI assistants such as Claude; every figure remains verifiable via the source links.

Business Model#

What the company does and how it earns its money; written AI-editorially, exclusively from the company's original reports, without any assessment of our own.

Integra LifeSciences Holdings Corporation is a global medical technology company that develops, manufactures, and markets surgical instruments, implants, and related products used primarily in neurosurgery, neurocritical care, and reconstructive surgery. The company distributes its products to hospitals, ambulatory surgery centers, and healthcare professionals through a direct sales force and distributor network across the United States and internationally. Integra's portfolio spans dural regeneration and repair matrices, cerebrospinal fluid management systems, ultrasonic surgical aspiration systems, cranial stabilization and positioning devices, and wound reconstruction products. Revenue is generated through direct sales of both capital equipment and single-use implant and instrument formats; the company does not report a distinct recurring-revenue segment in its public financial disclosures.

Current Status#

Summary of the most recent reporting period: core figures, drivers and management statements; written editorially from the current original report, every figure backed by a source number.

Integra LifeSciences reported second-quarter 2026 revenues of $418.8 million, an increase of 0.8% on a reported basis and 0.7% on an organic basis versus the prior-year period ³¹. Adjusted earnings per diluted share were $0.56, up from $0.45 in Q2 2025, while GAAP gross margin expanded to 52.5% from 50.4% in the prior year ³⁰ ³¹. The company initiated production at its Braintree manufacturing facility and confirmed it remains on track for the planned fourth-quarter 2026 relaunch of SurgiMend ³¹. Full-year 2026 organic revenue growth and adjusted EPS guidance were reaffirmed, while reported revenue guidance was adjusted to reflect a stronger U.S. dollar ³¹.

Management commentary on the 2026-Q2 results (8-K-EX99.1, 2026-07-29):

„Our second-quarter performance reflects meaningful progress on our most important priorities. We are improving supply reliability, advancing quality, and returning products to market with discipline. The Braintree facility is now producing and ramping to support the planned SurgiMend relaunch later this year.“ – Stuart Essig, Chairman and CEO ³¹

„At the same time, we are seeing the benefits of a more aligned commercial organization while we continue to reduce our balance sheet leverage. Supported by our broad portfolio, attractive markets, and focused leadership team, we are strengthening our operating foundation and enhancing our ability to deliver sustainable long-term shareholder value.“ – Stuart Essig, Chairman and CEO ³¹

Revenue · 2026-Q2419$m+0.8 % vs. 2025-Q2

Net profit · 2026-Q24$m+100.9 % vs. 2025-Q2

EPS · 2026-Q20.06$+101.0 % vs. 2025-Q2

Revenue trend

Guidance

For FY2026, the company guides organic revenue growth to 0.8% to 3.3% (confirmed); EPS (non-GAAP) to $2.40 to $2.50 (confirmed); Revenue to $1.654 billion to $1.695 billion (raised). ³¹.

Profitability

GAAP operating income was $19.3 million for Q2 2026, and GAAP net income was $4.5 million, compared to a net loss of $484.1 million in Q2 2025; the improvement was primarily attributable to the absence of a prior-year goodwill impairment charge ³⁰. Adjusted EBITDA increased to $78.4 million, or 18.7% of revenue, from $71.2 million, or 17.1% of revenue, in Q2 2025 ³¹. Free cash flow for the quarter was $10.5 million, derived from operating cash flow of $22.8 million less capital expenditures of $12.3 million ¹³¹.

Leverage

Net debt at June 30, 2026 was $1,521.7 million, and the consolidated total leverage ratio stood at 4.1x ³¹. Cash on hand was $214.4 million at quarter-end ¹³¹. Operating cash flows increased by $34.9 million in the first half of 2026 versus the same period of 2025, reflecting reduced quality and operational issues ³⁰.

Management view

Full-year 2026 organic revenue growth guidance of 0.8% to 3.3% and adjusted earnings per share guidance of $2.40 to $2.50 were reaffirmed ³¹. The company confirmed the Q4 2026 SurgiMend commercial relaunch plan remains on schedule ³¹. The Mayfield Ghost Base Unit Post, initially launched in the U.S. in September 2025, was introduced to European, Asian, Australian, and New Zealand markets through the first half of 2026 ³⁰.

Change

Reported revenue guidance was adjusted to $1.654 billion to $1.695 billion from a prior range of $1.662 billion to $1.702 billion, reflecting the impact of a stronger U.S. dollar on international revenue ³¹. The FDA issued a Warning Letter in December 2024 related to quality system issues at three manufacturing facilities; the company continued submitting responses and remediation efforts through Q2 2026 ³⁰. A restructuring initiative approved in Q4 2025 targeting $12.3 million in total costs recorded $3.8 million in charges in the first half of 2026, following $8.5 million incurred in full-year 2025 ³⁰.

Risks (current)

The company's Cincinnati, Ohio manufacturing facility sustained flood damage on July 17, 2026; based on current assessment the company does not expect a material adverse effect, though the evaluation remains ongoing ³⁰. U.S. tariffs on imported goods have increased costs of goods sold; the company submitted $17.6 million in IEEPA tariff refund claims as of June 30, 2026, expecting recovery through Phase 3 of CAPE and vendor refunds ³⁰. Additional risk factors include geopolitical tensions and trade barriers affecting suppliers and customers, third-party payor reimbursement and coverage pressure, increasing industry competition, difficulties controlling procurement and manufacturing costs, and exposure to geographic tax law changes ³⁰ ³¹.

New this reporting period

The Braintree manufacturing facility commenced production in June 2026, achieving an operational milestone in the company's quality remediation and supply recovery program that enables the planned SurgiMend product relaunch ³⁰ ³¹. As of the Q2 2026 filing, the SurgiMend PMA remains approvable pending GMP status following the FDA's determination in July 2024, with full approval expected in 2027 ³⁰. The DuraSorb PMA application advanced following completion of one-year patient follow-up milestones, with PMA approval also targeted for 2027 ³⁰.

Price & Chart#

Interactive price chart (TradingView) and the trend of key figures from the core tables. The price chart loads only after a click; at that point a connection to TradingView is established.

Daily candles with news and earnings markers. Loads only on click.

Advertisement · affiliate links; we may earn a commissionAffiliate partnerships help us keep these reports free and regularly updated.

Share-Price Drivers#

Factors the company itself names as material for its business development (IR-based); reproduced neutrally, no price forecast and no assessment of our own.

Manufacturing remediation and product return-to-market for the Tissue Technologies franchise
After the 2023 Boston facility voluntary recall (²⁶), PriMatrix and Durepair returned to market in 2026-Q1 (²⁹) and the Braintree facility began production in Q2 2026 (³¹), directly conditioning the recovery of tissue-based revenue; the same period saw net income turn positive at $4.5M and adj_eps rise to $0.56 (¹³¹)

Braintree manufacturing facility operationalization
Facility reached production in Q2 2026 (³¹), enabling the return of PriMatrix and Durepair to market in 2026-Q1 (²⁹) and supporting planned SurgiMend production in Q4 2026 (²⁹)

Tissue Reconstruction segment traction
Tissue Reconstruction revenue of $108.8M in 2026-Q1 grew 6.7%, outpacing the larger Specialty Surgery segment (²⁹)

Specialty Surgery (core neurosurgery/instruments) revenue
Largest segment at $283.1M in 2026-Q1 with growth of 0.9%, broadly flat (²⁹); overall growth flag is flat (¹³¹)

SurgiMend PMA and relaunch timeline
SurgiMend PMA approval is targeted for the first half of 2026 (³⁰) with relaunch planned for Q4 2026 (³¹), and a DuraSorb PMA for breast reconstruction is planned (³⁰); commercialization dates remain forward-looking

Acclarent ENT acquisition and ENT contribution
ENT revenue of $166.4M grew 22.7% (²⁷) following the Acclarent ENT business acquisition (²⁶)

Profitability and cost-model recovery
Operating income improved to $19.3M and net income turned positive at $4.5M in 2026-Q2 (¹³¹) after prior-quarter losses; profitability change flag is positive and guidance is confirmed (¹³¹), aided by the simplified operating model implemented February 2026 (²⁷)

Sector trend: Reported segment KPIs are mixed but stabilizing: Specialty Surgery demand is roughly flat while Tissue Reconstruction and ENT show renewed growth (²⁹, ²⁷), and group profitability metrics (operating income, adj_eps) are recovering alongside restored manufacturing capacity (¹³¹, ³¹).

Event Timeline#

This timeline collects the material events from the original reports: guidance changes, revenue and margin signals, strategy shifts, product and M&A announcements. Events are grouped by quarter (most recent first); the grey tag before each event names the event type, the date is the publication date of the source. Management quotes open the quarter block as direct quotes. Per quarter we show the three most defining events; more can be expanded per quarter, older years are collapsed. Every event carries its source as a superscript, clickable number.

Overview: one dot per event · click jumps to the period

2026 · 7 events

2026-Q2 · Apr – Jun 2026

Net income turned positive 2026-07-29
GAAP net income of $4.5 million versus net loss of $484.1 million in Q2 2025; improvement primarily due to absence of prior-year goodwill impairment charge, not operational improvement ³⁰

Guidance cut 2026-07-29
Reported revenue guidance range lowered to $1.654 billion-$1.695 billion from $1.662 billion-$1.702 billion to reflect stronger U.S. dollar; organic growth and adjusted EPS guidance of $2.40-$2.50 reaffirmed ³¹

Strategic pivot 2026-07-29
Braintree manufacturing facility became operational in June 2026 and began production ramp-up to support planned SurgiMend relaunch in Q4 2026 ³⁰

Cash flow inflection 2026-07-29
Operating cash flow reached 22.8 USDm vs 8.9 USDm in 2025-Q2 (×2.6). ¹³¹

2026-Q1 · Jan – Mar 2026

„Our first‑quarter results reflected solid product demand and the continued impact of our transformation efforts. We are seeing improving performance across the organization as operational rigor and improved execution take hold.“ – Mojdeh Poul, President and Chief Executive Officer ²⁹

earnings 2026-05-05
GAAP net loss narrowed to $(4.6) million from $(25.3) million in Q1 2025, primarily due to reduced quality and operational issues ²⁹

Margin expanding 2026-05-05
Adjusted EBITDA margin expanded to 19.4% from 16.6% in Q1 2025, driven by higher revenues and reduced Braintree remediation costs ²⁹

Guidance raised 2026-05-05
Adjusted EPS guidance raised to $2.40-$2.50 from $2.30-$2.40, reflecting Q1 benefit from IEEPA tariff refund ²⁹

2025 · 13 events

2025-Q4 · Oct – Dec 2025

„Earlier this month we implemented a key element of our transformation plan - a simplified operating model that improves alignment, execution, and accountability. This is critical to our long-term margin improvement plan and a key contributor to our previously communicated savings of $25-$30 million in 2026. Combined with focused portfolio prioritization and disciplined capital allocation, these actions reinforce the foundation for long-term sustainable growth, innovation, and performance.“ – Mojdeh Poul, president and chief executive officer ²⁷

Revenue decelerating ◦ 2026-02-26
Q4 revenues of $434.9M declined 1.7% reported and 2.5% organically; Tissue Technologies fell 12.8% including Wound Reconstruction down 21.4% ²⁷

Guidance initiated 2026-02-26
2026 full-year revenue guidance of $1,662-$1,702M (1.6%-4.1% reported growth) and adjusted EPS of $2.30-$2.40 issued ²⁷

Strategic pivot 2026-02-26
Simplified operating model implemented with restructuring initiative approved in Q4 2025 targeting $25-$30M in cost savings in 2026 through productivity and efficiency initiatives ²⁷

2025-Q3 · Jul – Sep 2025

„In the third quarter, we continued to see healthy demand across our portfolio. While revenue was impacted by two supply interruptions, we delivered strong profitability and cash flow through disciplined cost management and operational efficiencies. We are making progress in implementing our comprehensive plan to systematically strengthen the entirety of our supply chain and quality management system, and we remain confident in our strategy to improve overall performance and drive the Company's transformation.“ – Mojdeh Poul, president and chief executive officer ²⁵

earnings 2025-10-30
Adjusted EBITDA increased to $78.5M (19.5% of revenue) from $61.8M (16.2% of revenue) in Q3 2024 ²⁵

Revenue accelerating ◦ 2025-10-30
Q3 revenues of $402.1M increased 5.6% reported and 5.0% organically, reversing negative organic trends from the prior two quarters ²⁵

Guidance cut 2025-10-30
2025 full-year guidance revised to reflect Q3 revenue and updated Q4 assumptions; full-year actuals of $1,635.2M came in below the $1.655-$1.680B range set at Q2 ²⁵

Operating income turned positive 2025-10-30
Operating income turned positive for the first time after 2 negative periods (-512.7 to +11.8 USDm). ¹²⁵

2025-Q2 · Apr – Jun 2025

„I am proud of our team's performance and execution in the second quarter. Our strong revenue performance is a testament to our disciplined progress and the solid underlying demand trends for our portfolio of neurosurgery and tissue technology products.“ – Mojdeh Poul, President and Chief Executive Officer ²³

earnings 2025-07-31
GAAP net loss of $484.1M in Q2 2025 primarily driven by $511.4M goodwill impairment across Tissue Technologies, Neurosurgery, and Instruments and ENT reporting units due to share price decline and operational challenges ²³

Margin compressing 2025-07-31
Adjusted gross margin declined to 60.7% from 65.2% in Q2 2024; adjusted EBITDA margin fell to 17.1% from 20.0% due to quality and operational issues ²³

Guidance cut 2025-07-31
Full-year revenue guidance updated to $1.655-$1.680B; adjusted EPS range reflecting ongoing quality and operational headwinds ²³

2025-Q1 · Jan – Mar 2025

„As I reflect on my first quarter at Integra and continue spending time across our operations and with employees, I remain inspired by the deep commitment of our teams to our customers and patients. I am also encouraged by the positive feedback I consistently receive from customers about the impact of our solutions and the value of our portfolio. I'm equally optimistic about the long-term growth and earnings potential of our differentiated offerings.“ – Mojdeh Poul, President and Chief Executive Officer ²¹

Revenue decelerating ◦ 2025-05-05
Q1 revenues of $382.7M grew 3.7% reported but declined 3.5% organically; Neurosurgery fell 4.7% organically on shipping holds and Tissue Technologies declined 9.1% organically due to quality and operational issues ²¹

Margin compressing 2025-05-05
Gross margin declined to 50.8% from 56.1% in Q1 2024; adjusted gross margin declined to 62.2% from 64.4%, both impacted by quality and operational issues ²⁰ ²¹

Guidance cut 2025-05-05
Full-year adjusted EPS guidance reduced to $2.19-$2.29, including estimated tariff impact of $(0.22) per share ²¹

2024 · 17 events

FY2024 · Jan – Dec 2024

Operating income halved 2025-02-25
Operating income more than halved YoY (111.5 to 28.4 USDm, -75%). ¹⁸

2024-Q4 · Oct – Dec 2024

„As I step into my role leading Integra, I am inspired by the strength of our portfolio, the dedication of our team, and the tremendous potential we have to grow and innovate in high-impact specialty markets. Our fourth-quarter results reflect this strength, with sequential revenue growth driven by robust demand for our leading brands, continued progress in expanding our global presence, and our ongoing commitment to improving supply reliability.“ – Mojdeh Poul, President and Chief Executive Officer ¹⁹

Revenue accelerating ◦ 2025-02-25
Q4 revenues of $442.6 million increased 3.5% on an organic basis, recovering from Q3 disruptions as shipping holds released in line with expectations ¹⁹

Strategic pivot 2025-02-25
FDA issued a warning letter in December 2024 relating to quality system issues at three manufacturing facilities (Mansfield, Plainsboro, Princeton) ¹⁸

Acquisition 2025-02-25
Acquired product rights for Durepair Regeneration Matrix from Medtronic for $45.0 million total consideration, expanding the neurosurgery portfolio ¹⁸

Operating income turned positive 2025-02-25
Operating income turned positive for the first time after 2 negative periods (-8.2 to +35.6 USDm). ¹²⁷

Net income turned positive 2025-02-25
Net income turned positive for the first time after 3 negative periods (-10.7 to +19.4 USDm). ¹²⁷

2024-Q3 · Jul – Sep 2024

„Our third-quarter results highlight the early progress we are making to identify and remediate the gaps in our quality management system. We are progressing with the implementation of our compliance master plan across our manufacturing and supply chain operations, which will position us to meet robust market demand and more consistently and reliably deliver to customers, patients, and shareholders.“ – Jan De Witte, President and CEO ¹⁷

Revenue decelerating ◦ 2024-11-04
Q3 revenues declined 8.6% on an organic basis; Neurosurgery declined 16.0% organically due to temporary shipping holds in CSF management and neuro monitoring ¹⁷

Margin compressing 2024-11-04
Gross margin fell to 52.6% from 57.1% in Q3 2023; adjusted EBITDA margin declined to 16.2% of revenue from 23.0%, driven by quality and operational disruptions ¹⁶ ¹⁷

Strategic pivot 2024-11-04
Mojdeh Poul announced as incoming President and Chief Executive Officer, joining January 6, 2025 ¹⁷

2024-Q2 · Apr – Jun 2024

„Our second quarter financial performance continues to reflect the persistent market demand for our diversified portfolio and the commitment of our teams. Using the learnings from our Boston facility, we are continuing a thorough analysis of our operations and are committed to enhancing the quality, reliability and resilience of our manufacturing operations and supply chain. The reduction in our full-year guidance reflects an updated view of our operational challenges and critical investments in our compliance improvement program that will allow our supply to meet our strong commercial demand strength over time.“ – Jan De Witte, President and Chief Executive Officer ¹⁵

Guidance cut 2024-07-29
Full-year 2024 revenue guidance reduced to $1.609–1.629 billion from the $1.672–1.687 billion level set in Q1, reflecting shipping hold volume losses and significant second-half quality compliance investments ¹⁵

Strategic pivot 2024-07-29
Compliance Master Plan initiated as a systematic quality and GMP remediation approach; temporary shipping holds placed on certain products expected to primarily impact Q3 revenues ¹⁵

Acquisition 2024-07-29
Acclarent, Inc. acquired from Ethicon for approximately $282 million, establishing Integra as a leading ENT provider; Acclarent contributed $31.3 million to Codman Specialty Surgical revenue in Q2 ¹⁴

Revenue accelerating 2024-07-29
Revenue growth accelerated to +9.7% YoY (prior period -3.1%). ¹²³

2024-Q1 · Jan – Mar 2024

„We are pleased with our strong first quarter financial performance, which reflects the strength of our diversified portfolio and the unwavering commitment of our colleagues worldwide to our customers and patients. As we look to the rest of the year, we remain focused on executing our key priorities, particularly on enhancing quality, reliability and resilience of our manufacturing operations and supply chain, advancing our new product pipeline, and integrating the Acclarent business and welcoming our new colleagues.“ – Jan De Witte, president and chief executive officer ¹³

Revenue decelerating ◦ 2024-05-06
Q1 revenues declined 3.1% reported and 2.5% organic, with the Boston facility recall depressing results by $15.2 million; organic growth excluding Boston impact was +1.6% ¹³

Margin compressing 2024-05-06
Gross margin fell to 56.1% from 61.1% in Q1 2023, driven by idle capacity costs and elevated manufacturing expenses at the Boston facility ¹²

Guidance raised 2024-05-06
Full-year 2024 revenue guidance raised to $1.672–1.687 billion from $1.603–1.618 billion, adding approximately $80 million for the Acclarent acquisition ¹³

Operating income halved 2024-05-06
Operating income more than halved YoY (36.4 to 4.0 USDm, -89%). ¹²

2023 · 18 events

2023-Q4 · Oct – Dec 2023

„In 2023, we saw stability in our markets and resilience of our product portfolio, which demonstrates the impact of our products and technologies on restoring patients' lives. Despite the operational challenges last year, I am extremely proud of our colleagues around the world for remaining focused on advancing our key pillars of growth and operational excellence, and for their unwavering commitment to our customers and patients.“ – Jan De Witte, President and Chief Executive Officer ¹¹

Margin compressing 2024-02-28
FY2023 adjusted EBITDA $369.7 million, down $41.6 million versus prior year; adjusted EBITDA margin declined 240 basis points to 24.0% ¹¹

Guidance initiated 2024-02-28
2024 guidance: revenues $1,603-$1,618 million (4.0-5.0% reported growth); adjusted EPS $3.15-$3.25 ¹¹

Acquisition 2024-02-28
Signed definitive agreement to acquire Acclarent ENT business from Johnson & Johnson for $275 million cash plus up to $5 million in regulatory milestone payments ¹¹

Net income halved 2024-02-28
Net income more than halved YoY (52.9 to 19.8 USDm, -63%). ¹¹⁹

2023-Q3 · Jul – Sep 2023

„Although the Boston returns weighed further on our third quarter results, we are on track to restart the Boston facility by the end of the year, and we also met two significant CereLink milestones with the relaunch in international markets and submission for regulatory approval in the U.S. At the same time, our strong organic growth performance in the Codman Specialty Surgical and Tissue Technologies businesses, excluding Boston, plus advances across our product pipeline, give us confidence in our long-range growth commitments.“ – Jan De Witte, President and Chief Executive Officer ⁹

Revenue decelerating ◦ 2023-10-25
Q3 revenues declined 0.7% reported and 0.4% organic; Tissue Technologies revenues fell 15.6% to $114.2 million due to Boston recall impact ⁹

Margin compressing 2023-10-25
Adjusted gross margin declined to 64.6% from 66.7% in the prior year; adjusted EBITDA declined to $88.1 million from $105.3 million ⁹

Guidance cut 2023-10-25
Full-year 2023 guidance revised to $1.541-$1.547 billion revenue and adjusted EPS $3.10-$3.14, from prior ranges of $1,602-$1,620 million and $3.43-$3.51 ⁹

Operating income halved 2023-10-25
Operating income more than halved YoY (65.0 to 26.6 USDm, -59%). ¹¹⁷

Net income halved 2023-10-25
Net income more than halved YoY (49.9 to 19.5 USDm, -61%). ¹¹⁷

2023-Q2 · Apr – Jun 2023

„The strong organic growth of our Codman Specialty Surgical segment and several product lines in our Tissue Technologies business demonstrate the resilience of our diversified portfolio of leading brands and technologies and strong market recovery. Excluding the impact of the Boston recall, we delivered solid, mid-single digit organic growth from the underlying business. We are confident in our plans for the CereLink relaunch and the restart of our Boston manufacturing facility, and we continue to advance our implant-based breast reconstruction (IBBR) PMA strategy.“ – Jan De Witte, President and Chief Executive Officer ⁷

Revenue decelerating ◦ 2023-07-27
Q2 revenues declined 4.2% reported and 2.7% organic; Tissue Technologies revenues fell 21.2% reported and 19.7% organic due to Boston recall impact ⁷

Margin compressing 2023-07-27
H1 gross margin percentage declined to 57.7% from 62.4% in the prior year period due to Boston recall expenses ⁶

Strategic pivot 2023-07-27
Voluntary recall of Boston facility products (March 2018-May 2023) initiated in May 2023; manufacturing halt extended; $12.9 million return provision and $24.1 million inventory write-off recorded ⁶

Operating income halved 2023-07-27
Operating income more than halved YoY (59.9 to 12.5 USDm, -79%). ¹¹⁵

Net income halved 2023-07-27
Net income more than halved YoY (44.8 to 4.2 USDm, -91%). ¹¹⁵

Segment divergence 2023-07-27
Tissue Technologies revenue grew +73.5% to 242.9 USDm in 2023-Q2 (64% of group revenue) while group revenue changed -4.1%. ⁶

2023-Q1 · Jan – Mar 2023

„Our first quarter sales performance continues to demonstrate the strength of our diverse portfolio. We experienced solid growth and demand across many of our product lines and saw positive dynamics in our markets. We remain focused on delivering profitable growth while making critical investments to support our long-term strategic objectives and commitments.“ – Jan De Witte, president and chief executive officer ⁵

Revenue accelerating ◦ 2023-04-26
Q1 revenues increased 1.1% reported and 4.6% organic; Codman Specialty Surgical +3.5% organic, Tissue Technologies +6.8% organic ⁵

Guidance confirmed 2023-04-26
Full-year 2023 revenue guidance of $1,602-$1,620 million and adjusted EPS $3.43-$3.51 reaffirmed ⁵

Strategic pivot 2023-04-26
Production at Boston manufacturing site paused in March while quality system upgrades were pulled forward into H1 2023 ⁵

Key Figures ($m)#

The company's core financial figures in three views, one below the other: fiscal years (as reported; after restatements the table shows the most recent filing version, marked), half-years (6-month basis, H2 = second half on its own) and quarters (3-month basis, not cumulative). Each row is one period, most recent first. Values with a dotted underline are clickable and show the raw value, the exact source location, the scale evidence and the source; derived values additionally show their formula and inputs. All values are extracted automatically from the filings; errors are possible; please verify decision-relevant figures yourself by clicking through to the linked original.

All figures serve only to support your own investment decision and are not a recommendation; the company's original reports are authoritative.

Basis Metric

Revenue ($m) · annual basis, as reported

Net income ($m) · annual basis, as reported

EPS ($) · annual basis, as reported

Operating cash flow ($m) · annual basis, as reported

Revenue ($m) · quarterly basis, as reported

Net income ($m) · quarterly basis, as reported

EPS ($) · quarterly basis, as reported

Operating cash flow ($m) · quarterly basis, as reported

Cash ($m) · annual basis, as reported

Debt ($m) · annual basis, as reported

Net Debt ($m) · annual basis, as reported

Capex ($m) · annual basis, as reported

FCF ($m) · annual basis, as reported

D&A ($m) · annual basis, as reported

Cash ($m) · quarterly basis, as reported

Debt ($m) · quarterly basis, as reported

Net Debt ($m) · quarterly basis, as reported

Capex ($m) · quarterly basis, as reported

FCF ($m) · quarterly basis, as reported

Shown: the most recent fiscal years. Full history since FY2016 is on record.

Fiscal years

Amounts in $m · EPS in $ per share · as reported

Period	Revenue	Op. income	Net income	EPS ($)	EPS adj. ($)	EBITDA (adj.)	OCF	Source
FY2025	1,635.2	-493.4	-516.5	-6.74	2.23	317.5	50.4	²⁶
FY2024	1,610.5	28.4	-6.9	-0.09	2.56	322.2	129.4	¹⁸
FY2023	1,541.6	111.5	67.7	0.84	3.10	369.7	140	¹⁰

Quarters

Amounts in $m · EPS in $ per share · as reported

Period	Published	Revenue	Op. income	Net income	EPS ($)	EPS adj. ($)	EBITDA (adj.)	FCF	Cash	Net Debt	Source
2026-Q2*	2026-07-29	418.8	19.3	4.5	0.06	0.56	78.4	10.5	214.4	1,521.7	¹³¹
2026-Q1*	2026-05-05	391.9	11.5	-4.6	-0.06	0.54	76.2	-5	236.8	1,513.4	¹²⁹
2025-Q4*	2026-02-26	434.9	23	-1.7	-0.02*	0.83	104.2	-5.4	235	1,494.5	¹²⁷
2025-Q3*	2025-10-30	402.1	11.8	-5.4	-0.07	0.54	78.5	25.8	232.2	1,476.7	¹²⁵
2025-Q2*	2025-07-31	415.6	-512.7	-484.1	-6.31	0.45	71.2	-11.2	217.9	1,474.9	²²
2025-Q1*	2025-05-05	382.7	-15.5	-25.3	-0.33	0.41	63.6	-40.2	239.1	1,463.3	¹²¹
2024-Q4*	2025-02-25	442.6	35.6	19.4	0.25*	0.97	104.9	21.1	246.4	1,414.7	¹⁸
2024-Q3*	2024-11-04	380.8	-8.2	-10.7	-0.14	0.41	61.8	-7.2	215.2	1,489.6	¹⁶
2024-Q2*	2024-07-29	418.2	-3	-12.4	-0.16	0.63	83.8	10.7	215.2	936.4	¹⁴
2024-Q1*	2024-05-06	368.9	4	-3.3	-0.04	0.55	71.8	0.3	591.9	579.1	¹¹³
2023-Q4*	2024-02-28	397	36	19.8	0.25	0.89	100.5	34.2	276.4	549.2	¹⁰
2023-Q3*	2023-10-25	382.4	26.6	19.5	0.24	0.76	88.1	13.7	273.7	576.4	⁸
2023-Q2*	2023-07-27	381.3	12.5	4.2	0.05	0.71	88.8	12.6	309.2	455.4	⁶
2023-Q1*	2023-04-26	380.8	36.4	24.2	0.29	0.74	92.3	12.5	307.4	461.8	¹⁰⁵

* derived: values with formula provenance (hover); Q4 = FY − 9M · H2 = FY − H1 · EPS via implied shares · net debt = financial debt − cash · FCF = OCF − |capex|.

Columns not reported in this reporting cadence are hidden: Op. income (adj.), Net Debt/EBITDA (not reported in any source for these periods).

Balance Sheet & Cash Flow ($m)#

Point-in-time balance sheet items (e.g. cash, financial debt) and cash flow items (operating cash flow, investments/capex) per fiscal year, half-year and quarter. Balance sheet values are as of the period end, flow items cover the period. Derived values are marked and are calculated, for example, as: net debt = financial debt − cash; free cash flow = operating cash flow − capex; the click popover shows formula and inputs. All values are extracted automatically from the filings; errors are possible; please verify decision-relevant figures yourself by clicking through to the linked original.

Fiscal years

Amounts in $m · as reported

Period	Published	Cash	Debt	Net Debt	D&A	OCF	Capex	FCF	Source
FY2025	2026-02-26	235	1,729.6	1,494.5	59.8	50.4	81.4	-31.1	¹³¹
FY2024	2025-02-25	246.4	1,661.1	1,414.7	63.7	129.4	104.4	25	¹²⁷
FY2023	2024-02-28	276.4	825.6	549.2	53.3	140	66.9	73.1	¹¹⁹

Quarters

Amounts in $m · as reported

Period	Published	Cash	Debt	Net Debt	OCF	Capex	FCF	Source
2026-Q2	2026-07-29	214.4	1,736.1	1,521.7	22.8	12.3	10.5	¹³¹
2026-Q1	2026-05-05	236.8	1,750.3	1,513.4	9.8	14.8	-5	¹²⁹
2025-Q4	2026-02-26	235	1,729.6	1,494.5	11.8	17.2	-5.4	¹²⁷
2025-Q3	2025-10-30	232.2	1,708.9	1,476.7	40.9	15.2	25.8	¹²⁵
2025-Q2	2025-07-31	217.9	1,692.8	1,474.9	8.9	20.1	-11.2	²²
2025-Q1	2025-05-05	239.1	1,702.4	1,463.3	-11.3	28.9	-40.2	¹²¹
2024-Q4	2025-02-25	246.4	1,661.1	1,414.7	50.7	29.6	21.1	¹⁸
2024-Q3	2024-11-04	215.2	1,704.7	1,489.6	22.5	29.6	-7.2	¹⁶
2024-Q2	2024-07-29	215.2	1,151.7	936.4	40.4	29.7	10.7	¹⁴
2024-Q1	2024-05-06	591.9	1,171	579.1	15.8	15.5	0.3	¹¹³
2023-Q4	2024-02-28	276.4	825.6	549.2	58.8	24.6	34.2	¹⁰
2023-Q3	2023-10-25	273.7	850.1	576.4	26.8	13.1	13.7	⁸
2023-Q2	2023-07-27	309.2	764.6	455.4	28.3	15.6	12.6	⁶
2023-Q1	2023-04-26	307.4	769.1	461.8	26.2	13.7	12.5	¹⁰⁵

Debt = long-term + current · Net debt = debt − cash · FCF = OCF − capex.

Revenue by Type (as of 2026-Q2 · USDm · 9/9)#

Revenue split by segment or product type, exactly as the company itself reports it. The basis is stated next to each value (3, 6 or 12 months); segment totals can deviate from group revenue (reconciliation/consolidation items). If the company changes its segment structure, older structures are kept in the expandable part. Rows in grey are no longer reported separately by the company; they show the last available figures and are never extrapolated.

Segment	Since	Period	Basis	Revenue	Growth	Source
Specialty Surgery	2026-Q1	2026-Q1	3M	283.1	0.9%	²⁹
Tissue Reconstruction	2026-Q1	2026-Q1	3M	108.8	6.7%	²⁹
ENT	2024-Q3	FY2025	3M	166.4	22.7%	²⁷
Neurosurgery	2023-Q4	FY2025	3M	827.7	3%	²⁷
Wound Reconstruction and Care	2023-Q4	FY2025	3M	323.5	-7.7%	²⁷
Instruments	2023-Q4	FY2025	3M	206.5	1.1%	²⁷
Private Label	2023-Q4	FY2025	3M	111.2	-4.4%	²⁷
Codman Specialty Surgical	2022-Q2	FY2025	3M	1,200.5	5%	²⁷
Tissue Technologies	2022-Q2	FY2025	3M	434.7	-6.9%	²⁷

Products & M&A (21/61 active+recent)#

Product announcements from the reports; market launches, approvals, partnerships; with first mention (date) and source. “Active/current” means: still mentioned in the most recent reports; what the company no longer mentions moves to the expandable part but is never deleted. Rows in grey are discontinued products.

Product/Line	Since	Status	Source
SurgiMend relaunch	2026-12	Launched	³¹
SurgiMend production	2026-12	Launched	²⁹
Durepair return to market (2×)	2026-03	Launched	²⁹
Simplified operating model implementation	2026-02	Launched	²⁷
DuraSorb PMA approval for multiple indications for IBBR	2026	Launched	²⁴
CUSA Clarity for Cardiac Surgery	2025-11	Launched	³⁰
PriMatrix relaunch	2025-09	Launched	²⁵
Mayfield Ghost Base Unit Post (2×)	2025-09	Launched	³⁰
Durepair relaunch	2025-09	Launched	²⁵
AERA Pediatric Registry (3×)	2025-07	Launched	²⁶
Profitability Initiative	2025-06	Launched	²³
Early relaunch of PriMatrix	2025	Launched	²⁷
Early relaunch of Durepair	2025	Launched	²⁷
CerebroFlo EVD catheter with Endexo technology	2025	Launched	²⁶
CereLink approval in Brazil, Philippines, UAE, Albania and India	2025	Launched	²⁴
Aurora Surgiscope 15mm x 60mm and 15mm x 80mm (2×)	2025	Launched	²⁶
Braintree facility operational (11×)	2024-06	Launched	²⁸
DuraSorb approval	2023-09	Launched	³⁰
Aurora Surgiscope next generation (2×)	2023-09	Launched	²⁴
SurgiMend PMA approval (3x)	2023-06	Launched	³⁰
SurgiMend breast reconstruction PMA filing (8×)	2021-09	Launched	²²
SurgiMend PMA approvable notification pending GMP certification	2024-12	Launched	¹⁹
DuraSorb PMA submission advancement	2024-12	Launched	¹⁹
CereLink market uptake	2024-12	Launched	¹⁹
Braintree facility equipment installation	2024-09	Launched	¹⁷
SurgiMend® PRS pre-market approval	2024-06	Launched	¹⁴
Boston facility relaunch	2024-06	Launched	¹¹
SurgiMend and PriMatrix relaunch	2024-03	Launched	¹³
MicroMatrix® Flex launch in U.S.	2024-03	Launched	¹⁴
MicroMatrix Flex U.S. commercial availability	2024-03	Launched	¹²
CereLink intracranial pressure monitoring system relaunch	2024-03	Launched	¹⁸
CereLink Monitor FDA 510(k) clearance (2×)	2024-02	Launched	¹⁰
MicroMatrix Flex U.S. launch	2024	Launched	²²
Boston manufacturing facility restart	2023-12	Launched	⁹
9mm Surgiscope FDA 510(k) clearance (2×)	2023-10	Launched	¹⁰
SurgiMend PMA supplement submission	2023-09	Launched	⁵
CereLink 510(k) premarket notification	2023-09	Launched	⁹
CUSA Electrosurgery Module launch (2×)	2023-08	Launched	¹⁰
CereLink ICP Monitor international limited release	2023-07	Launched	¹⁰
DuraSorb IDE clinical study (5x)	2023-06	Launched	¹⁰
DuraGen portfolio expansion (China and Japan approvals)	2023-06	Launched	⁷
Boston facility product recall (3x)	2023-05	Launched	²⁶
DuraSorb PMA clinical trial	2023-03	Launched	⁵
MicroMatrix and Certas Plus Programmable Valve launch in Europe	2023-01	Launched	¹⁰
Cytal launch in Europe	2023-01	Launched	¹⁰
MicroMatrix launch in Europe	2023	Launched	¹⁰
MicroMatrix Flex	2023	Launched	²⁴
MicroMatrix	2023	Launched	⁶
DuraGen Secure approval in Japan	2023	Launched	¹²
DuraGen Secure	2023	Launched	⁶
DuraGen Plus	2023	Launched	⁶
Cytal and MicroMatrix Europe launch	2023	Launched	¹²
Certas Plus approval in China (2x)	2023	Launched	²⁴
Certas Plus Programmable Valve launch in Europe	2023	Launched	¹⁰
Certas Plus Programmable Valve	2023	Launched	⁶
Acclarent AERA Eustachian Tube Dilation System expanded pediatric indications 510(k) clearance	2023	Launched	²⁴
CereLink relaunch (8x)	2022-08	Launched	⁷
Neutus EVD system launch in China	2022-06	Launched	⁴
NeuraGen 3D Nerve Guide Matrix launch	2022	Launched	¹²
CUSA Lap Tip launch (9×)	2022	Launched	⁸
Aurora Evacuator with Coagulation device launch	2022	Launched	⁴

▸ More products & M&A (older) (+46)

M&A (12)#

All recorded acquisitions (purchases) and divestitures/exits with date, short description and source; deliberately including smaller transactions that summaries often miss. Purchase prices appear only where the company itself has disclosed them. Rows in grey are cancelled transactions; the cancellation date is shown in the row.

Acquisitions · 8Divestitures/exits · 2older: 2 (in the table)

Acquisitions

Transaction / stake	Date	Type	Source
Acclarent ENT acquisition (3×)	2024-06	Completed	¹¹
Acclarent	2024-04	Completed	²⁶
Durepair Dural Regeneration Matrix (6×)	2024	Completed	²⁶
Acclarent acquisition from Ethicon, Inc. (2×)	2023-12	Completed	¹⁴
$150 million accelerated share repurchase	2023-03	Completed	⁵
Surgical Innovation Associates (3×)	2022-12	Completed	¹⁰
SIA acquisition	2022-12	Completed	¹⁰
ACell, Inc. acquisition	2021-01	Completed	¹⁰
Rebound Therapeutics Corporation acquisition	2019-01	Completed	¹⁰
Arkis Biosciences, Inc. acquisition	2019-01	Completed	¹⁰

Divestitures / exits

Transaction / stake	Date	Type	Source
TWC business divestiture to Gentell Inc. (3×)	2022-08	Divested	¹⁰
CereLink product removal	2022-08	Divested	¹²

Reported KPIs (as disclosed) (186)#

Figures the company discloses itself in addition to the standard financials; order intake, recurring revenue, user or unit counts, adjusted measures. These “story KPIs” usually slip through standard databases; here they are collected as reported, with no calculation of our own. Important: the definition comes from the company itself and can differ from firm to firm; period and source are stated next to every value.

Company-specific KPIs verbatim from the filings (English, as disclosed; not normalised). Balance-sheet and boilerplate items filtered.

Date	Period	KPI	Value / change	Source
2026-07-29	2026-Q2	Total Liquidity	approximately $496 million	³¹
2026-07-29	2026-Q2	Consolidated Total Leverage Ratio	4.1x	³¹
2026-07-29	2026-Q2	Tissue Reconstruction Revenue	$109,492	³⁰
2026-07-29	2026-Q2	Specialty Surgery Revenue	$309,269	³⁰
2026-07-29	2026-Q2	Short-Term Investments	$59.7	³⁰
2026-07-29	2026-Q2	Selling, General and Administrative as % of Revenue	41.2%	³⁰
2026-07-29	2026-Q2	Research and Development as % of Revenue	5.8%	³⁰
2026-07-29	2026-Q2	Operating Cash Flow	$32,605	³⁰
2026-07-29	2026-Q2	IEEPA Tariff Refund Claims Submitted	$17.6	³⁰
2026-07-29	2026-Q2	Gross Margin Percentage	52.5%	³⁰
2026-07-29	2026-Q2	Consolidated Total Leverage Ratio	4.10	³⁰
2026-07-29	2026-Q2	Cash and Cash Equivalents	$214.4	³⁰
2026-07-29	2026-Q2	Capital Expenditures	$27.2	³⁰
2026-05-05	2026-Q1	Working Capital	825.2 million	²⁸
2026-05-05	2026-Q1	Total Liquidity	$488 million	²⁹
2026-05-05	2026-Q1	Short-Term Investments	28.7 million	²⁸
2026-05-05	2026-Q1	Organic Revenue Growth Q1	1.3%	²⁹
2026-05-05	2026-Q1	Organic Revenue Growth FY2026	0.8% to 3.3%	²⁹
2026-05-05	2026-Q1	Non-US Cash	196.9 million	²⁸
2026-05-05	2026-Q1	Net Debt	$1.6 billion	²⁹
2026-05-05	2026-Q1	Gross Margin GAAP	55.4%	²⁹
2026-05-05	2026-Q1	Consolidated Total Leverage Ratio Covenant	5.00	²⁸
2026-05-05	2026-Q1	Consolidated Total Leverage Ratio	4.12	²⁸
2026-05-05	2026-Q1	Consolidated Total Leverage Ratio	4.1x	²⁹
2026-05-05	2026-Q1	Cash and Short-Term Investments	$265.5 million	²⁹
2026-05-05	2026-Q1	Cash and Equivalents	236.8 million	²⁸
2026-05-05	2026-Q1	Adjusted Gross Margin	64.1%	²⁹
2026-05-05	2026-Q1	Adjusted EBITDA Margin	19.4%	²⁹
2026-02-26	FY2025	Working Capital	$703.6 million	²⁶
2026-02-26	FY2025	Valuation Allowance Deferred Tax Assets	$22.6 million	²⁶
2026-02-26	FY2025	State Net Operating Loss Carryforwards	$85.4 million	²⁶
2026-02-26	FY2025	Non-US Cash and Equivalents	$193.0 million	²⁶
2026-02-26	FY2025	Gross Deferred Tax Assets	$278.1 million	²⁶
2026-02-26	FY2025	Foreign Net Operating Loss Carryforwards	$142.8 million	²⁶
2026-02-26	FY2025	Federal Net Operating Loss Carryforwards	$46.7 million	²⁶
2026-02-26	FY2025	Consolidated Total Leverage Ratio	4.50	²⁶
2026-02-26	2025-Q4	Total Liquidity	approximately 516 million	²⁷
2026-02-26	2025-Q4	Consolidated Total Leverage Ratio	4.5x	²⁷
2026-02-26	2025-Q4	Cash and Short-Term Investments	263.7 million	²⁷
2026-02-26	2025-Q4	adjusted gross margin Q4 2025	61.7%	²⁷
2026-02-26	2025-Q4	adjusted gross margin Q4 2024	65.2%	²⁷
2026-02-26	2025-Q4	adjusted gross margin FY 2025	61.9%	²⁷
2026-02-26	2025-Q4	adjusted gross margin FY 2024	64.5%	²⁷
2026-02-26	2025-Q4	adjusted EBITDA margin Q4 2025	24.0%	²⁷
2026-02-26	2025-Q4	adjusted EBITDA margin Q4 2024	23.7%	²⁷
2026-02-26	2025-Q4	adjusted EBITDA margin FY 2025	19.4%	²⁷
2026-02-26	2025-Q4	adjusted EBITDA margin FY 2024	19.4%	²⁷
2025-10-30	2025-Q3	Total Liquidity	$549.8 million	²⁵
2025-10-30	2025-Q3	total debt	$1.8 billion	²⁵
2025-10-30	2025-Q3	operating cash flow Q3	$40.9 million	²⁵
2025-10-30	2025-Q3	Net Debt	$1.6 billion	²⁵
2025-10-30	2025-Q3	Consolidated Total Leverage Ratio	4.3x	²⁵
2025-10-30	2025-Q3	Cash and Short-Term Investments	$267.9 million	²⁵
2025-10-30	2025-Q3	Adjusted Gross Margin	62.9%	²⁵
2025-10-30	2025-Q3	GAAP gross margin	51.5%	²⁵
2025-10-30	2025-Q3	covenant requirement	5.00	²⁴
2025-10-30	2025-Q3	Consolidated Total Leverage Ratio	4.35	²⁴
2025-07-31	2025-Q2	Total Liquidity	1.14 billion	²³
2025-07-31	2025-Q2	Net Debt	1,591,130 (USD in thousands)	²³
2025-07-31	2025-Q2	Consolidated Total Leverage Ratio	4.5x	²³
2025-07-31	2025-Q2	adjusted gross margin Q2 2025	60.7%	²³
2025-07-31	2025-Q2	adjusted gross margin Q2 2024	65.2%	²³
2025-07-31	2025-Q2	working capital	213.0 million	²²
2025-07-31	2025-Q2	short-term investments	35.7 million	²²
2025-07-31	2025-Q2	non-U.S. subsidiaries cash	180.0 million	²²
2025-07-31	2025-Q2	covenant requirement	5.00	²²
2025-07-31	2025-Q2	Consolidated Total Leverage Ratio	4.53	²²
2025-07-31	2025-Q2	Cash and Cash Equivalents	217.9 million	²²
2025-05-05	2025-Q1	Working Capital	188.8 million	²⁰
2025-05-05	2025-Q1	Short-Term Investments	34.2 million	²⁰
2025-05-05	2025-Q1	non-U.S. subsidiaries cash and cash equivalents	182.7 million	²⁰
2025-05-05	2025-Q1	cash and cash equivalents	239.1 million	²⁰
2025-05-05	2025-Q1	Total liquidity	1.16 billion	²¹
2025-05-05	2025-Q1	Total leverage ratio	4.3x	²¹
2025-05-05	2025-Q1	GAAP gross margin	50.8%	²¹
2025-05-05	2025-Q1	Consolidated Total Leverage Ratio covenant requirement	5.00	²⁰
2025-05-05	2025-Q1	Consolidated Total Leverage Ratio	4.30	²⁰
2025-05-05	2025-Q1	Cash and short-term investments	273 million	²¹
2025-02-25	FY2024	Working Capital	159.6 million	¹⁸
2025-02-25	FY2024	Valuation allowance	15.5 million	¹⁸
2025-02-25	FY2024	Short-term investments interest rate sensitivity	0.3 million	¹⁸
2025-02-25	FY2024	Short-Term Investments	27.2 million	¹⁸
2025-02-25	FY2024	Net operating loss carryforwards state	46.5 million	¹⁸
2025-02-25	FY2024	Net operating loss carryforwards foreign	106.7 million	¹⁸
2025-02-25	FY2024	Net operating loss carryforwards federal	51.2 million	¹⁸
2025-02-25	FY2024	Impairment charge Boston	4.6 million	¹⁸
2025-02-25	FY2024	Estimated effective tax rate 2025	36.7%	¹⁸
2025-02-25	FY2024	Effective tax rate 2024	61.9%	¹⁸
2025-02-25	FY2024	Effective tax rate 2023	16.4%	¹⁸
2025-02-25	FY2024	Debt interest rate sensitivity	8.1 million	¹⁸
2025-02-25	FY2024	Consolidated Total Leverage Ratio	4.04	¹⁸
2025-02-25	FY2024	Cash interest rate sensitivity	2.5 million	¹⁸
2025-02-25	FY2024	Cash and Equivalents	246.4 million	¹⁸
2025-02-25	2024-Q4	Total Liquidity	approximately 1.2 billion	¹⁹
2025-02-25	2024-Q4	Net Debt	1.5 billion	¹⁹
2025-02-25	2024-Q4	Consolidated Total Leverage Ratio	4.0x	¹⁹
2025-02-25	2024-Q4	Cash and Short-Term Investments	approximately 273 million	¹⁹
2024-11-04	2024-Q3	Revenue	$380.8 million	¹⁶
2024-11-04	2024-Q3	Gross margin	52.6%	¹⁶
2024-11-04	2024-Q3	Consolidated Total Leverage Ratio	3.99	¹⁶
2024-11-04	2024-Q3	Total liquidity	$1.18 billion	¹⁷
2024-11-04	2024-Q3	Total balance sheet debt	$1.81 billion	¹⁷
2024-11-04	2024-Q3	GAAP gross margin	52.6%	¹⁷
2024-11-04	2024-Q3	Consolidated total leverage ratio	4.0x	¹⁷
2024-11-04	2024-Q3	Cash and short-term investments	$277 million	¹⁷
2024-11-04	2024-Q3	Adjusted EBITDA margin	16.2%	¹⁷
2024-07-29	2024-Q2	Working capital	$784.0	¹⁴
2024-07-29	2024-Q2	Total revenues	$418,175	¹⁴
2024-07-29	2024-Q2	Total liquidity	1.18 billion	¹⁵
2024-07-29	2024-Q2	Total balance sheet debt	1.83 billion	¹⁵
2024-07-29	2024-Q2	Tissue Technologies segment revenue	116,414 (USD in thousands)	¹⁵
2024-07-29	2024-Q2	Tissue Technologies organic growth	5.7%	¹⁵
2024-07-29	2024-Q2	Short-term investments	$81.7	¹⁴
2024-07-29	2024-Q2	Organic growth excluding Boston	0.3%	¹⁵
2024-07-29	2024-Q2	Organic growth	2.3%	¹⁵
2024-07-29	2024-Q2	Gross margin on total revenues	$225,917	¹⁴
2024-07-29	2024-Q2	Gross margin as % of total revenues	54.0%	¹⁴
2024-07-29	2024-Q2	Consolidated total leverage ratio	3.8x	¹⁵
2024-07-29	2024-Q2	Codman Specialty Surgical segment revenue	301,761 (USD in thousands)	¹⁵
2024-07-29	2024-Q2	Codman Specialty Surgical organic growth	0.9%	¹⁵
2024-07-29	2024-Q2	Cash and short-term investments	297 million	¹⁵
2024-07-29	2024-Q2	Cash and cash equivalents	$215.2	¹⁴
2024-07-29	2024-Q2	Adjusted EBITDA margin	20.0%	¹⁵
2024-05-06	2024-Q1	Working Capital	$1,113.3 million	¹²
2024-05-06	2024-Q1	Short-Term Investments	$71.2 million	¹²
2024-05-06	2024-Q1	Cash, non-US subsidiaries	$210.6 million	¹²
2024-05-06	2024-Q1	Cash and equivalents, total	$591.9 million	¹²
2024-05-06	2024-Q1	Total liquidity	approximately $1.54 billion	¹³
2024-05-06	2024-Q1	Total balance sheet debt	$1.86 billion	¹³
2024-05-06	2024-Q1	Tissue Technologies revenues	$112.4 million	¹³
2024-05-06	2024-Q1	Neurosurgery organic growth	6.3%	¹³
2024-05-06	2024-Q1	Consolidated total leverage ratio	3.2x	¹³
2024-05-06	2024-Q1	Codman Specialty Surgical revenues	$256.4 million	¹³
2024-05-06	2024-Q1	Cash plus short-term investments	$663 million	¹³
2024-02-28	FY2023	Working capital 2023	751.1 million	¹⁰
2024-02-28	FY2023	Working capital 2022	840.6 million	¹⁰
2024-02-28	FY2023	short term investments 2023	32.7 million	¹⁰
2024-02-28	FY2023	non-US cash 2023	246.9 million	¹⁰
2024-02-28	FY2023	cash and cash equivalents 2023	276.4 million	¹⁰
2024-02-28	FY2023	cash and cash equivalents 2022	456.7 million	¹⁰
2024-02-28	2023-Q4	Total liquidity	1.5 billion	¹¹
2024-02-28	2023-Q4	Organic revenue growth full-year excl. Boston	5.5%	¹¹
2024-02-28	2023-Q4	Organic revenue growth full-year	0%	¹¹
2024-02-28	2023-Q4	Organic revenue growth Q4 excl. Boston	3.6%	¹¹
2024-02-28	2023-Q4	Organic revenue growth Q4	-1.2%	¹¹
2024-02-28	2023-Q4	Net debt	1.2 billion	¹¹
2024-02-28	2023-Q4	Consolidated total leverage ratio	3.0x	¹¹
2024-02-28	2023-Q4	Cash and short-term investments	309 million	¹¹
2024-02-28	2023-Q4	Adjusted EBITDA margin full-year	24.0%	¹¹
2024-02-28	2023-Q4	Adjusted EBITDA margin Q4	25.3%	¹¹
2023-10-25	2023-Q3	Working Capital	671.5 million	⁸
2023-10-25	2023-Q3	unsatisfied performance obligations 12 months	50%	⁸
2023-10-25	2023-Q3	non-US subsidiaries cash	247.7 million	⁸
2023-10-25	2023-Q3	deferred compensation plan fair value	5.4 million	⁸
2023-10-25	2023-Q3	contract liability short-term	8.1 million	⁸
2023-10-25	2023-Q3	contract liability long-term	8.1 million	⁸
2023-10-25	2023-Q3	cash and cash equivalents	273.7 million	⁸
2023-10-25	2023-Q3	Total liquidity	$1.48 billion	⁹
2023-10-25	2023-Q3	GAAP gross margin prior year	61.5%	⁹
2023-10-25	2023-Q3	GAAP gross margin	57.1%	⁹
2023-10-25	2023-Q3	Consolidated total leverage ratio	3.0x	⁹
2023-10-25	2023-Q3	Cash and cash equivalents	273,732 (USD in thousands)	⁹
2023-10-25	2023-Q3	Adjusted gross margin prior year	66.7%	⁹
2023-10-25	2023-Q3	Adjusted gross margin	64.6%	⁹
2023-10-25	2023-Q3	Adjusted EBITDA margin prior year	27.3%	⁹
2023-10-25	2023-Q3	Adjusted EBITDA margin	23.0%	⁹
2023-07-27	2023-Q2	working capital June 30 2023	673.8 million	⁶
2023-07-27	2023-Q2	working capital Dec 31 2022	840.6 million	⁶
2023-07-27	2023-Q2	non-US subsidiaries cash June 30 2023	267.1 million	⁶
2023-07-27	2023-Q2	cash and cash equivalents June 30 2023	309.2 million	⁶
2023-07-27	2023-Q2	cash and cash equivalents Dec 31 2022	456.7 million	⁶
2023-07-27	2023-Q2	Total liquidity	1,610,000	⁷
2023-07-27	2023-Q2	Total balance sheet debt	1,440,000 (USD in thousands)	⁷
2023-07-27	2023-Q2	Reported revenue growth (Q2 2023)	-4.2%	⁷
2023-07-27	2023-Q2	Organic revenue growth excluding Boston recall (Q2 2023)	5.5%	⁷
2023-07-27	2023-Q2	Organic revenue growth (Q2 2023)	-2.7%	⁷
2023-07-27	2023-Q2	GAAP gross margin (Q2 2023)	54.3%	⁷
2023-07-27	2023-Q2	Consolidated total leverage ratio	2.6x	⁷
2023-07-27	2023-Q2	Adjusted gross margin (Q2 2023)	67.6%	⁷
2023-07-27	2023-Q2	Adjusted EBITDA margin (Q2 2023)	23.3%	⁷
2023-04-26	2023-Q1	Total Liquidity	approximately $1.61 billion	⁵
2023-04-26	2023-Q1	total debt	$1.45 billion	⁵
2023-04-26	2023-Q1	operating cash flow	26,156 (USD in thousands)	⁵
2023-04-26	2023-Q1	Net Debt	$1.15 billion	⁵
2023-04-26	2023-Q1	Consolidated Total Leverage Ratio	2.5x	⁵
2023-04-26	2023-Q1	Cash and Equivalents	$307 million	⁵

▸ Earlier KPIs (+171)

Guidance Tracking (latest per metric/period · 24/45)#

All management forecasts (guidance) and their later outcome. Types: fiscal-year targets as well as quarterly/half-year targets; per metric and period the most recent statement applies, older versions can be expanded. The status is checked automatically against the actuals reported later: open (period still running), met, beaten, missed. For ranges (“X to Y”) reaching the range counts. Logged neutrally, no estimate of our own, no assessment.

Actuals: revenue in $m · EPS in $ per share · ratios in %

For period	Guided on	Metric	Guided	Actual	Verdict	Direction	Source
FY2026	2026-07-29	organic revenue growth	0.8–3.3%	–	pending	confirmed	³¹
FY2026	2026-05-05	EPS (non-GAAP)	2.4–2.5	–	pending	confirmed	³¹
FY2026	2026-02-26	Revenue	1,654–1,695	–	pending	raised	³¹
2026-Q3	2026-07-29	Revenue	410–425	–	pending	initiated	³¹
2026-Q3	2026-07-29	EPS (non-GAAP)	0.53–0.61	–	pending	initiated	³¹
2026-Q3	2026-07-29	organic growth	1.9–5.7%	–	pending	initiated	³¹
2026-Q2	2026-05-05	Revenue	410–425	418.8	in line	initiated	²⁹
2026-Q2	2026-05-05	EPS (non-GAAP)	0.44–0.52	0.56	beat	initiated	²⁹
2026-Q1	2026-02-26	Revenue	375–390	391.9	beat	initiated	²⁷
2026-Q1	2026-02-26	EPS (non-GAAP)	0.37–0.45	0.54	beat	initiated	²⁷
FY2025	2025-10-30	Revenue	1,620–1,640	1,635.2	in line	–	²⁵
FY2025	2025-10-30	EPS (non-GAAP)	2.19–2.24	2.23	in line	–	²⁵
FY2025	2025-02-25	Revenue growth (YoY)	2.4–6.5%	1.5	miss	initiated	¹⁹
FY2025	2025-02-25	organic growth	1–5%	–	–	initiated	¹⁹
2025-Q4	2025-10-30	Revenue	420–440	434.9	in line	initiated	²⁵
2025-Q4	2025-10-30	EPS (non-GAAP)	0.79–0.84	0.83	in line	initiated	²⁵
2025-Q3	2025-07-31	Revenue	410–420	402.1	miss	confirmed	²³
2025-Q3	2025-07-31	EPS (non-GAAP)	0.4–0.45	0.54	beat	confirmed	²³
2025-Q2	2025-05-05	Revenue	390–400	415.6	beat	confirmed	²¹
2025-Q2	2025-05-05	EPS (non-GAAP)	0.4–0.45	0.45	in line	confirmed	²¹
2025-Q1	2025-02-25	Revenue	375–385	382.7	in line	initiated	¹⁹
2025-Q1	2025-02-25	EPS (non-GAAP)	0.4–0.45	0.41	in line	initiated	¹⁹
2025-Q1	2025-02-25	Revenue growth (YoY)	1.6–4.4%	3.7	in line	initiated	¹⁹
2025-Q1	2025-02-25	organic growth	-6.2–-3.5%	–	–	initiated	¹⁹
FY2024	2024-11-04	EPS (non-GAAP)	2.41–2.49	2.56	beat	updated	¹⁷
FY2024	2024-02-28	Revenue	1,609–1,619	1,610.5	in line	updated	¹⁷
FY2024	2024-02-28	Organic growth	4–5%	–	–	initiated	¹¹
2024-Q4	2024-11-04	Revenue	441–451	442.6	in line	initiated	¹⁷
2024-Q4	2024-11-04	EPS (non-GAAP)	0.81–0.89	0.97	beat	initiated	¹⁷
2024-Q3	2024-07-29	Revenue	372–382	380.8	in line	initiated	¹⁵
2024-Q3	2024-07-29	EPS (non-GAAP)	0.36–0.44	0.41	in line	initiated	¹⁵
2024-Q2	2024-05-06	Revenue	411–416	418.2	beat	initiated	¹³
2024-Q2	2024-05-06	EPS (non-GAAP)	0.6–0.65	0.63	in line	initiated	¹³
2024-Q1	2024-02-28	Revenue	360–365	368.9	beat	initiated	¹¹
2024-Q1	2024-02-28	EPS (non-GAAP)	0.53–0.57	0.55	in line	initiated	¹¹
FY2023	2023-07-27	Revenue	1,541–1,547	1,541.6	in line	confirmed	⁹
FY2023	2023-07-27	EPS (non-GAAP)	3.1–3.14	3.1	in line	confirmed	⁹
2023-Q4	2023-10-25	Revenue	397–403	397	in line	initiated	⁹
2023-Q4	2023-10-25	EPS (non-GAAP)	0.89–0.93	0.89	in line	initiated	⁹
2023-Q3	2023-07-27	Revenue	386–390	382.4	miss	initiated	⁷
2023-Q3	2023-07-27	EPS (non-GAAP)	0.76–0.8	0.76	in line	initiated	⁷
2023-Q2	2023-04-26	Revenue	396–400	381.3	miss	initiated	⁵
2023-Q2	2023-04-26	EPS (non-GAAP)	0.75–0.79	0.71	miss	initiated	⁵
2023-Q1	2023-02-22	Revenue	370–376	380.8	beat	initiated	³
2023-Q1	2023-02-22	EPS (non-GAAP)	0.72–0.76	0.74	in line	initiated	³

▸ show older periods (+30)

Development#

A condensed summary per reporting period as running text: what changed operationally, which drivers management names, how earnings and cash flow developed. Most recent period first, grouped by year; each text is written from the original report of that period, superscript numbers lead to the source.

FY2026

In fiscal year 2026, Integra LifeSciences reported first-half revenues of $810.7 million, with Q1 at $391.9 million (up 2.4% reported, 1.3% organic) ¹²⁹ and Q2 at $418.8 million (up 0.8% reported, 0.7% organic) ¹³¹. Adjusted EPS improved year-over-year in both quarters, reaching $0.54 in Q1 ¹²⁹ and $0.56 in Q2 ¹³¹, while adjusted EBITDA margins expanded as quality remediation costs declined. The Tissue Reconstruction segment achieved 6.7% reported and 6.4% organic growth in Q1, driven by the return to market of PriMatrix and Durepair products, while the Specialty Surgery segment posted an organic decline of 0.6% ²⁹. The Braintree manufacturing facility became operational in June 2026, positioning the company for a planned SurgiMend relaunch in Q4 2026 ³⁰. Full-year 2026 reported revenue guidance was trimmed to $1.654 billion-$1.695 billion reflecting U.S. dollar strength, while organic growth and adjusted EPS guidance of $2.40-$2.50 were reaffirmed ³¹.

FY2025

Integra LifeSciences reported FY2025 total revenues of $1,635.2 million, up 1.5% on a reported basis but down 0.7% organically, with the Codman Specialty Surgical segment growing 5.0% offset by a Tissue Technologies segment decline of 6.9% ²⁶. Gross margin fell from 54.8% in 2024 to 50.9%, reflecting quality and operational disruptions tied to an FDA warning letter received December 2024, higher manufacturing costs, and $19.9 million in tariff costs ²⁶. A non-cash goodwill impairment of $511.4 million recorded in Q2 2025 across the Tissue Technologies, Neurosurgery, and Instruments and ENT reporting units – driven by share price decline and operational challenges – produced a GAAP net loss of $516.5 million for the year, while adjusted EPS declined to $2.23 from $2.56 in 2024 ²⁶ ²⁷. Operating cash flow fell $79.0 million to $50.4 million and free cash flow was negative $31.1 million, weighed by higher manufacturing costs and tariff payments ²⁶. The Acclarent ENT acquisition completed April 2024 contributed to Codman Specialty Surgical revenue growth, while the Braintree manufacturing facility remained on track for mid-2026 operationalization to support pending SurgiMend and DuraSorb PMA approvals ²⁶.

FY2024

Integra LifeSciences reported FY2024 total revenues of $1,610.5 million, up 4.5% on a reported basis from $1,541.6 million in 2023, with the Acclarent acquisition–completed April 1, 2024 for approximately $282 million–accounting for the majority of reported growth; on an organic basis revenues declined approximately 1.3%, as quality and operational disruptions including temporary shipping holds implemented mid-year and the ongoing impact of the voluntary Boston facility product recall suppressed volume, most acutely in Neurosurgery during Q3 ¹⁸ ¹⁹. Full-year gross margin contracted to 54.8% from 57.4%, reflecting Boston recall-related charges, Acclarent inventory step-up amortization, and underutilized manufacturing capacity ¹⁸. GAAP net loss was $6.9 million versus net income of $67.7 million in 2023, while adjusted EPS declined to $2.56 from $3.10 and full-year adjusted EBITDA margin compressed approximately 400 basis points to 20.0% ¹⁸ ¹⁹. Additional developments during the year included the October 2024 acquisition of Durepair Regeneration Matrix product rights for $45 million, an FDA warning letter issued in December 2024 regarding quality system issues at three manufacturing facilities, and the planned transition of PriMatrix and SurgiMend manufacturing to a new Braintree, Massachusetts facility targeted for first-half 2026 operationalization ¹⁸.

FY2023

Integra LifeSciences reported FY2023 revenues of $1,541.6 million, a decline of 1.0% on a reported basis and flat organically versus $1,557.7 million in FY2022, with growth in the Codman Specialty Surgical segment offset by a significant decline in the Tissue Technologies segment driven by the Boston manufacturing facility recall ¹⁰ ¹¹. The voluntary recall of Boston-manufactured products distributed between March 2018 and May 2023 resulted in a $24.6 million inventory write-off, an $18.7 million product return provision, and $15.0 million in idle capacity charges, compressing gross margin to 57.4% from 62.3% in the prior year ¹⁰. The Codman Specialty Surgical segment grew $39.4 million (3.9%), while the Tissue Technologies segment declined $55.5 million (10.3%); excluding the Boston recall and TWC divestiture impacts, the Tissue Technologies segment increased approximately $32.0 million driven by strong sales in IDRT and MicroMatrix/Cytal ¹⁰. Net income decreased to $67.7 million ($0.84 per diluted share) from $180.6 million ($2.16 per diluted share) in FY2022, with adjusted EPS of $3.10 compared to $3.36 in the prior year and full-year adjusted EBITDA declining $41.6 million to $369.7 million ¹⁰ ¹¹. In December 2023, the company signed a definitive agreement to acquire Acclarent Inc. from Johnson & Johnson for $275 million cash plus up to $5 million in regulatory milestone payments, targeting completion by Q2 2024 ¹⁰.

Sources: official investor relations documents#

All original documents used, with type (e.g. quarterly, half-year, annual report), publication date and a direct link to the filing (EDINET/SEC/IR). Every superscript number in the report points to an entry in this list; so every figure can be traced back to its place in the original.

49 documents · 2016 – 2026 · SEC EDGAR (USA)

#	Document type	Published	Link
#1	8-K-EX99.1	2023-01-10	Open
#2	10-K	2023-02-22	Open
#3 / #103	8-K-EX99.1	2023-02-22	Open
#4	10-Q	2023-04-26	Open
#5 / #105	8-K-EX99.1	2023-04-26	Open
#6	10-Q	2023-07-27	Open
#7 / #107	8-K-EX99.1	2023-07-27	Open
#8 / #108	10-Q	2023-10-25	Open
#9 / #109	8-K-EX99.1	2023-10-25	Open
#10	10-K	2024-02-28	Open
#11 / #111	8-K-EX99.1	2024-02-28	Open
#12	10-Q	2024-05-06	Open
#13 / #113	8-K-EX99.1	2024-05-06	Open
#14	10-Q	2024-07-29	Open
#15 / #115	8-K-EX99.1	2024-07-29	Open
#16	10-Q	2024-11-04	Open
#17 / #117	8-K-EX99.1	2024-11-04	Open
#18	10-K	2025-02-25	Open
#19 / #119	8-K-EX99.1	2025-02-25	Open
#20	10-Q	2025-05-05	Open
#21 / #121	8-K-EX99.1	2025-05-05	Open
#22	10-Q	2025-07-31	Open
#23 / #123	8-K-EX99.1	2025-07-31	Open
#24	10-Q	2025-10-30	Open
#25 / #125	8-K-EX99.1	2025-10-30	Open
#26	10-K	2026-02-26	Open
#27 / #127	8-K-EX99.1	2026-02-26	Open
#28	10-Q	2026-05-05	Open
#29 / #129	8-K-EX99.1	2026-05-05	Open
#30	10-Q	2026-07-29	Open
#31 / #131	8-K-EX99.1	2026-07-29	Open

▸ More rows (+16)

Older sources (+18)

#	Document type	Published	Link
#201	10-Q	2016-04-27	Open
#202	10-Q	2016-07-28	Open
#203	10-Q	2016-10-28	Open
#204	10-K	2017-02-23	Open
#206	10-Q	2017-02-23	Open
#207	10-K	2017-02-23	Open
#205	10-Q	2017-07-26	Open
#209	10-K	2018-03-01	Open
#208	10-Q	2018-07-26	Open
#211	10-K	2019-02-26	Open
#210	10-Q	2019-07-25	Open
#215	10-K	2020-02-21	Open
#212	10-Q	2020-05-07	Open
#213	10-Q	2020-08-10	Open
#214	10-Q	2020-10-29	Open
#216	10-Q	2021-04-29	Open
#217	10-Q	2021-07-29	Open
#218	10-Q	2021-11-02	Open

▸ More rows (+3)

FAQ#

Is there a management forecast (guidance) for FY2026?

Yes. Management has issued targets for FY2026, including organic revenue growth. The guidance tracking chapter shows all targets and checks them against the actuals reported later; neutral, with no estimate of our own.

Where can I find the official investor relations documents of Integra LifeSciences Holdings Corporation?

The sources chapter links all 65 original filings used (SEC filings) with type, publication date and a direct link; every figure in the report carries a source number.